EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Comparison of Therapeutic Outcomes Between Concomitant Therapy and Tailored Therapy for Helicobacter pylori : A Multicenter, Prospective, and Randomized Study

Young Sin Cho, Sun Moon Kim, Sun Hyung Kang, Hee Seok Moon, Jae Kyu Sung, Ki Bae Bang, Sung Hyeok Ryou, Ki Bae Kim, Hae Joung Sul, Seung-Woo Lee iD

Helicobacter · 2025

DOI: 10.1111/hel.70040 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2025. Verfasst von Young Sin Cho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Jeil Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The increasing trend of clarithromycin resistance in Helicobacter pylori ( H. pylori ) is the primary cause of failure of standard triple therapy. Concomitant therapy is recommended as an alternative in regions with high rates of clarithromycin resistance. Recently, tailored therapies based on resistance testing have emerged as viable treatment approaches. We aimed to compare the eradication rates and adverse effects of concomitant and tailored therapies. Materials and Methods We enrolled 319 patients diagnosed with H. pylori infection using dual‐priming oligonucleotide (DPO) polymerase chain reaction (PCR) tests conducted in six hospitals across the Daejeon and Chungcheong regions of Korea. Based on DPO‐PCR results, patients were randomly assigned to either the concomitant therapy group (non‐bismuth quadruple therapy) or the tailored therapy group (standard triple therapy for clarithromycin‐sensitive cases and bismuth quadruple therapy for clarithromycin‐resistant cases). Demographics, eradication success rates, adverse effects, and patient compliance were assessed. Data were analyzed using modified intention‐to‐treat (mITT) and per‐protocol (PP) analyses.

Results

The eradication rate was significantly higher in the tailored therapy group than in the concomitant therapy group in PP analysis (92.62% vs. 85.21%, p = 0.026). The severity of adverse effects was significantly greater in the concomitant therapy group than in the tailored therapy group ( p = 0.025).

Conclusion

Considering the high eradication success rate and low severity of adverse effects, tailored therapy based on DPO‐PCR is preferable to concomitant therapy without resistance testing for the treatment of H. pylori infection. Trial Registration Clinical Research Information Service (CRIS): KCT0004162

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriAnti-Bacterial AgentsHumansMaleFemaleMiddle AgedTreatment OutcomeProspective StudiesDrug Therapy, CombinationAdultClarithromycinAgedRepublic of KoreaDrug Resistance, BacterialBismuthProton Pump Inhibitors

Stichwörter der Autor:innen

Helicobacter pyloriantibiotic resistanceconcomitant therapyeradicationtailored therapy

Substanzen

Anti-Bacterial AgentsClarithromycinBismuthProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
  • Department of Internal Medicine, College of Medicine, Konyang University, Daejeon, Korea.
  • Department of Internal Medicine, Chungnam National University, College of Medicine, Daejeon, Korea.
  • Department of Internal Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea.
  • Internal Medicine, Chungbuk National University Hospital, Chungbuk National University School of Medicine, Cheongju, Korea.
  • Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.

ORCID-Profile: Seung-Woo Lee

Förderung

  • Jeil Pharmaceutical

Zitieren

APA

Cho, Y. S., Kim, S. M., Kang, S. H., Moon, H. S., Sung, J. K., Bang, K. B., Ryou, S. H., Kim, K. B., Sul, H. J., & Lee, S. W. (2025). Comparison of Therapeutic Outcomes Between Concomitant Therapy and Tailored Therapy for Helicobacter pylori : A Multicenter, Prospective, and Randomized Study. Helicobacter. https://doi.org/10.1111/hel.70040

Vancouver

Cho YS, Kim SM, Kang SH, Moon HS, Sung JK, Bang KB, et al. Comparison of Therapeutic Outcomes Between Concomitant Therapy and Tailored Therapy for Helicobacter pylori : A Multicenter, Prospective, and Randomized Study. Helicobacter. 2025. doi:10.1111/hel.70040

BibTeX
@article{Cho2025,
  author = {Cho, Young Sin and Kim, Sun Moon and Kang, Sun Hyung and Moon, Hee Seok and Sung, Jae Kyu and Bang, Ki Bae and Ryou, Sung Hyeok and Kim, Ki Bae and Sul, Hae Joung and Lee, Seung-Woo},
  title = {Comparison of Therapeutic Outcomes Between Concomitant Therapy and Tailored Therapy for Helicobacter pylori : A Multicenter, Prospective, and Randomized Study},
  journal = {Helicobacter},
  year = {2025},
  doi = {10.1111/hel.70040}
}
Kostenlos starten →